---
title: "Durvalumab - Transitional Cell Carcinoma"
sidebar: mydoc_sidebar
permalink: db11714-mesh-d002295-1.html
toc: false 
---


Path ID: `DB11714_MESH_D002295_1`
{% include image.html url="images/db11714-mesh-d002295-1.png" file="db11714-mesh-d002295-1.png" alt="db11714-mesh-d002295-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| DB:DB11714 | Durvalumab | Drug |
| UniProt:Q9NZQ7 | Programmed cell death 1 ligand 1 | Protein |
| GO:0042098 | T cell proliferation | BiologicalProcess |
| GO:0042110 | T cell activation | BiologicalProcess |
| GO:0002424 | T cell mediated immune response to tumor cell | BiologicalProcess |
| MESH:D002295 | Transitional cell carcinoma | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Durvalumab | DECREASES ACTIVITY OF | Programmed Cell Death 1 Ligand 1 |
| Programmed Cell Death 1 Ligand 1 | NEGATIVELY REGULATES | T Cell Proliferation |
| Programmed Cell Death 1 Ligand 1 | NEGATIVELY REGULATES | T Cell Activation |
| T Cell Proliferation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Activation | POSITIVELY CORRELATED WITH | T Cell Mediated Immune Response To Tumor Cell |
| T Cell Mediated Immune Response To Tumor Cell | NEGATIVELY CORRELATED WITH | Transitional Cell Carcinoma |
|---------|-----------|---------|

Comment: This medication is reserved for tumors that express PD-L1 or have high mutation burden.

Reference: 
  - [https://go.drugbank.com/drugs/DB11714](https://go.drugbank.com/drugs/DB11714)
  - [https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors](https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors)
